AEterna Zentaris (TSX:AEZS) Machinery, Furniture, Equipment

: C$0.63 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

AEterna Zentaris's Machinery, Furniture, Equipment for the quarter that ended in Dec. 2023 was C$0.63 Mil.

AEterna Zentaris's quarterly Machinery, Furniture, Equipment stayed the same from Jun. 2023 (C$0.00 Mil) to Sep. 2023 (C$0.00 Mil) but then increased from Sep. 2023 (C$0.00 Mil) to Dec. 2023 (C$0.63 Mil).

AEterna Zentaris's annual Machinery, Furniture, Equipment increased from Dec. 2021 (C$0.45 Mil) to Dec. 2022 (C$0.55 Mil) and increased from Dec. 2022 (C$0.55 Mil) to Dec. 2023 (C$0.63 Mil).

AEterna Zentaris Machinery, Furniture, Equipment Historical Data

The historical data trend for AEterna Zentaris's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Machinery, Furniture, Equipment

0.56

0.55

0.45

0.55

0.63

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Machinery, Furniture, Equipment																0.55	-	-	-	0.63

AEterna Zentaris Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Machinery, Furniture, Equipment

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.